The findings of this meta-analysis indicate that intrauterine administration of G-CSF during the luteal phase and at ovulation can reduce the risk of miscarriage in patients with recurrent miscarriage and increase the live birth rate, highlighting its significant clinical application value in the treatment of recurrent miscarriage. This evidence concerns the gene CSF3 and spontaneous abortion.